Top 10 Growth Stocks with High Insider Ownership
PorAinvest
martes, 12 de agosto de 2025, 2:07 pm ET1 min de lectura
VMD--
Viemed Healthcare, Inc. (NASDAQ: VMD), a US-based provider of home medical equipment and post-acute respiratory healthcare services, reported robust financial results for the second quarter of 2025. The company's market cap stands at $275.38 million, and it is expected to see significant earnings growth at a forecasted annual rate of 26.3%, outpacing the US market [1].
Key highlights from the Q2 2025 financial results include record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), representing a remarkable 115.1% increase from the same period in 2024. Adjusted EBITDA grew 11.5% to $14.3 million, indicating solid operational efficiency despite expansion efforts [2].
Operational highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. The company completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025, marking a strategic pivot into women's health. This acquisition broadens Viemed's addressable market and leverages its established home care infrastructure [2].
Viemed's Q2 results demonstrate impressive growth momentum across all key financial metrics. The company raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million. The strong operating cash flow during the quarter continues to contribute to a rock-solid balance sheet, with $20 million in cash and $55 million available in credit facilities [2].
The company's insider ownership stands at 13%, with recent insider trading showing more buying than selling, indicating confidence in the company's future prospects. Viemed's share repurchase program, which involves buying back up to 1.98 million shares by June 2026, aims to enhance shareholder value [1].
Viemed Healthcare's strategic expansion into women's health and its focus on improving patient outcomes through high-touch and high-tech services position it well for continued growth. The company's strong financial position and operational efficiency underscore its potential for robust performance in the coming quarters.
References
[1] https://sg.finance.yahoo.com/news/spotlight-viemed-healthcare-2-other-173546255.html
[2] https://www.stocktitan.net/news/VMD/viemed-healthcare-announces-second-quarter-2025-financial-7xbejomf5g3r.html
Viemed Healthcare is a US-based home medical equipment and post-acute respiratory healthcare services provider with a market cap of $275.38 million. The company's earnings are expected to grow significantly at a forecasted annual rate of 26.3%, outpacing the US market. Recent guidance raised revenue expectations for 2025, and Viemed announced a share repurchase program. Insider trading shows more buying than selling recently.
Title: Viemed Healthcare's Strong Q2 Results and Strategic ExpansionViemed Healthcare, Inc. (NASDAQ: VMD), a US-based provider of home medical equipment and post-acute respiratory healthcare services, reported robust financial results for the second quarter of 2025. The company's market cap stands at $275.38 million, and it is expected to see significant earnings growth at a forecasted annual rate of 26.3%, outpacing the US market [1].
Key highlights from the Q2 2025 financial results include record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), representing a remarkable 115.1% increase from the same period in 2024. Adjusted EBITDA grew 11.5% to $14.3 million, indicating solid operational efficiency despite expansion efforts [2].
Operational highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. The company completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025, marking a strategic pivot into women's health. This acquisition broadens Viemed's addressable market and leverages its established home care infrastructure [2].
Viemed's Q2 results demonstrate impressive growth momentum across all key financial metrics. The company raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million. The strong operating cash flow during the quarter continues to contribute to a rock-solid balance sheet, with $20 million in cash and $55 million available in credit facilities [2].
The company's insider ownership stands at 13%, with recent insider trading showing more buying than selling, indicating confidence in the company's future prospects. Viemed's share repurchase program, which involves buying back up to 1.98 million shares by June 2026, aims to enhance shareholder value [1].
Viemed Healthcare's strategic expansion into women's health and its focus on improving patient outcomes through high-touch and high-tech services position it well for continued growth. The company's strong financial position and operational efficiency underscore its potential for robust performance in the coming quarters.
References
[1] https://sg.finance.yahoo.com/news/spotlight-viemed-healthcare-2-other-173546255.html
[2] https://www.stocktitan.net/news/VMD/viemed-healthcare-announces-second-quarter-2025-financial-7xbejomf5g3r.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios